REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of enrollment of the first three dose expansion arms of COVALENT- 111, with a total of over 260 type 2 diabetes patients enrolled. Forward-Looking Statements About CO ...

Core Insights - Biomea Fusion, Inc. has completed enrollment for the first three dose expansion arms of the COVALENT-111 study, with over 260 type 2 diabetes patients participating [1][4] Group 1: Study Overview - COVALENT-111 is a multi-site, randomized, double-blind, placebo-controlled Phase I/II clinical trial focusing on type 2 diabetes patients who are uncontrolled by standard care [2][5] - The Phase II portion includes multiple dose escalation and expansion cohorts, evaluating the drug BMF-219 over varying durations and dosages [2][5] Group 2: Drug Details - BMF-219 is being evaluated for its ability to provide durable glycemic control, with early results showing promising outcomes after just 4 weeks of treatment [4] - The expansion phase aims to investigate the effects of longer dosing regimens of BMF-219, specifically over 8 to 12 weeks [4] Group 3: Company Background - Biomea Fusion is focused on developing oral covalent small molecules to treat metabolic diseases and genetically defined cancers, offering potential advantages over conventional drugs [6][7] - The company utilizes its proprietary FUSION™ System to design and develop next-generation medicines aimed at maximizing clinical benefits for patients [7]

Possible short-squeeze targets Source: Barchart The surge in GameStop (NYSE: GME) and AMC Entertainment (NYSE: AMC) stocks, which added over 100% in their value in just one day, has hinted at the craze that was gripping the stock market when meme mania hit and has already caused short-sellers to lose over $1 billion, while GME and AMC stocks added over $6 billion to their market caps in the process. Now, the question is whether this surge is sustainable, whether it can spread to other stocks deemed 'meme st ...

Exhibit 99.1 Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) - Biomea Fusion, Inc. ("Biomea" or "the Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported first quarter 2024 financial results and corporate highlights. DIABETES • R ...

| --- | --- | --- | --- | --- | |--------------------------------------------------------------|-------|--------------|-------|-------------| | Operating expenses: | | March \n2024 | 31, | 2023 | | Research and development | $ | 33,776 | $ | 24,395 | | General and administrative | | 7,283 | | 5,636 | | Total operating expenses | | 41,059 | | 30,031 | | Loss from operations | | (41,059 ) | | (30,031 ) | | Interest and other income, net | | 1,998 | | 980 | | Net loss | $ | (39,061 ) | $ | (29,051 ) | | Other ...

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (NASDAQ:BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea's board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of the Company's c ...

Exhibit 99.1 Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights • In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells. o After just a 4-week treatment period in type 2 diabetes patients, who had previously failed standard of care (HbA1c > 7.0% and < 10%), BMF-219 demonstrated continued glycemic control ...

Custom Scaffold Creation: We create novel chemical scaffolds using a computational platform to exploit the unique structural elements of a specific target protein. We then screen these scaffolds with in-house technologies to select the optimal candidates for further construction and design. This evaluation process is intended to increase the probability of having multiple targeted compounds that can advance through the discovery process and into the clinic. · Molecule Optimization/Refinement: Using our prop ...

There’s a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they’re intuitive and easier to engage.Buying something and hoping that it appreciates in value represents an organically sensible strategy. It’s the reason why people collect everything from baseball cards to luxury Swiss watches. Stated differently, it doesn’t take much to explain the rationale behind short-squeeze stocks to buy.On the other hand, shorting a stock represents an incredibly complex affair by comparison. F ...

Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17th Annual ATTD Conference Highlighting BMF-219's Novel Mechanism of Action in Patients with Type 2 Diabetes Patients in COVALENT-111 are displaying improved glycemic control while off therapy out to Week 26 following the 28-day treatment with BMF-219, supporting enhanced pancreatic islet function as the mechanism of actionBMF-219 was generally well tolerated with no serious adverse events and no adverse event-re ...